- Email: [email protected]
Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram in patients with rheumatic disorders
ARTICLE IN PRESS
Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram in patients with rheumatic disorders Beatrice Adamptey, OD, MSc, Christopher J. Rudnisky, MD, MPH, Ian M. MacDonald, MSc, MDCM ABSTRACT Objective: To report the effect of hydroxychloroquine therapy cessation on the multifocal electroretinogram (mfERG) in a case series of patients with rheumatic disease suspected to have retinopathy. Methods: Comprehensive data were retrospectively reviewed on 14 patients from a total of 50 cases who discontinued hydroxychloroquine due to suspected toxicity. Patients were followed for 4 years after the cessation of therapy. mfERG testing had been part of original screening for hydroxychloroquine retinopathy and was continued after therapy cessation at 6-month intervals. Descriptive statistics, independent sample t test, and one-way analysis of variance with repeated measures and post hoc analysis were conducted to determine patients’ clinical characteristics and changes in the mfERG after therapy cessation, respectively. Results: All 14 patients were female; 12 were treated for rheumatoid arthritis and 2 for systemic lupus erythematosus. Three groups were identified: (i) 9 patients in whom the responses of the mfERG recovered to within normative values after cessation of hydroxychloroquine therapy, (ii) 3 who experienced limited recoveries, and (iii) 1 patient whose mfERG response was unchanged. There was no significant difference (p > 0.05) in the clinical characteristics of these patients. However, the proportional reduction of mfERG ring 1, 2, and 3 amplitudes from age normal responses at the time of discontinuation of drug use for the first and second groups of patients was significantly different, with more reduction in group 2 (p < 0.05). Conclusion: Early detection of hydroxychloroquine retinopathy through screening and subsequent therapy discontinuation could result in recovery of the mfERG ring amplitude response and preservation of visual function.
Hydroxychloroquine is widely used in North America to manage inflammatory and autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.1,2 Hydroxychloroquine is preferred over chloroquine because of its relatively safer profile, with less adverse effect on retinal structure and function.3,4 Hydroxychloroquine retinopathy is a concern for patients, especially those taking the drug for more than 5 years.5,6 With the application of more sensitive screening tests capable of detecting retinopathy at the premaculopathy stage, such as multifocal electroretinography (mfERG) and spectral domain optical coherence tomography (SD-OCT), the prevalence of hydroxychloroquine retinopathy could be higher than previously reported.5,6 There is currently no available treatment for hydroxychloroquine retinopathy.7 Once diagnosed, cessation is recommended to limit or halt progression of retinal toxicity. Only a few small studies have reported the course of hydroxychloroquine retinopathy after cessation of therapy using more sensitive tests such as the mfERG.7 9 Marmor and Hu10 and Mititelu et al.8 reported that the course of hydroxychloroquine retinopathy (recovery, progression, or stability) was determined by the stage of disease at which patients discontinued therapy. They indicated that disease progressed even with cessation, thus advocating for early detection. In 2016, the American Academy of Ophthalmology recommended the use of more sensitive and specific tests, such
as the mfERG, for the early detection of hydroxychloroquine retinopathy.5,11 Our study therefore reports the outcome of a cohort of patients on hydroxychloroquine for rheumatic disorders based on the American Academy of Ophthalmology guidelines and the response of a select number for whom cessation of therapy had been recommended. The study also determined what factors influenced the recovery or progression of abnormal mfERG responses to guide physicians’ decisions on drug discontinuation to prevent vision loss.
TAGEDH1METHODOLOGYTAGEDEN We retrospectively reviewed the medical records of 623 patients screened for hydroxychloroquine retinopathy with the use of mfERG at the Royal Alexandra Hospital, Edmonton, from January 2008 and December 2016. The medical records of these patients were captured in a secure diagnostic electronic database at the Eye Institute of Alberta . In general, patients in this dataset had mfERG testing as a baseline test, or to document functional loss from concurrent maculopathy or to rule out hydroxychloroquine retinopathy. The study received a waiver of consent from the Health Research Ethics Board of the University of Alberta and operational approval from Alberta Health Services, Edmonton.
© 2019 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved. https://doi.org/10.1016/j.jcjo.2019.05.013 ISSN 0008-4182 CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
1
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al. Inclusion criteria
Cases of hydroxychloroquine retinopathy were included based on the opinions of 2 independent observers reviewing fundus examination, fundus photography, fundus autofluorescence, mfERG, SD-OCT, and 10-2 Humphrey visual field (HVF). Hydroxychloroquine retinopathy was defined as at least 2 abnormal functional tests (mfERG, SD-OCT, or 10-2 HVF), patient symptoms, and an abnormal fundus examination. Testing abnormalities were defined as a full or partial ring scotoma on a 10-2 HVF examination,6 or disruption of the photoreceptor ellipsoid zone on SD-OCT.6,12 14 For the mfERG, hydroxychloroquine retinopathy was defined as ring 1, 2, and 3 amplitudes reduced below the lower limit of the 95% confidence interval of age normal data (Table 1), with or without elevated ring 1/2 and/ 1/3 ratios, and with or without delayed implicit time.13,15,16 Exclusion criteria
Cases without agreement of independent examiners on presumed hydroxychloroquine retinopathy and those for whom insufficient information was available during a period of follow-up were excluded. For some patients, follow-up mfERG testing was not ordered by the referring clinician. Subgroup analysis
Cases in which hydroxychloroquine retinopathy was identified and therapy stopped were followed up to 4 years after the cessation of therapy. These cases had clear, legible 10-2 HVF, SD-OCT, and mfERG test images; multiple testing with mfERG (no 60 cycle noise)17; no artifacts on SD-OCT imaging; and reliable 10-2 HVF (<20% false-negative and false-positive rates and <10% fixation losses). Visual field test acquisition
Visual fields were generated by the HVF 10-2 program visual field analyser, white stimulus test target, and SITA-standard protocol (Carl Zeiss Meditec, Dublin, Calif).
Spectral domain optical coherence tomography image acquisition
Foveal centred volume scans with Spectralis tracking laser tomography (Spectralis Heidelberg Engineering, Carlsbad, Calif) system were acquired by 4 ophthalmic technicians. 10-2 HVF field and SD-OCT images are reported where available in Supplementary Figure 2, which is available online. Two patients with coincident retinal disease and/or 8 patients with incomplete data were excluded from the analysis. For each patient, data were collected on therapy duration (start and end date of therapy, daily drug dose (mg/kg), cumulative drug dose (kg), height (m), weight (kg), sex, age, and racial background. Multifocal electroretinogram response acquisition
mfERG imaging was recorded in accordance with the standards of the International Society for Clinical Electrophysiology of Vision18,19 with DTL fibre electrodes using the 2015 model of the Espion system 6+ (Diagnosys LLC, Lowell, Mass) software. The pupils of patients were dilated with 1% tropicamide to a size of >8 mm before the acquisition of mfERG responses. The m-sequence-controlled, 61-hexagon black and white stimulus pattern was used traversing a visual field of 30° on either side of the point of fixation. The black and white hexagons had a luminance of 1000 and 0 cd/m2, respectively. The waveforms (negative trough N1 and positive peak P1) generated from continuous stimulation of the retina by each of the 61 hexagons were processed through the 10 100 Hz bandpass filter. The Espion system version 6+ software analysed the response of the first-order kernel. The average rings 1 3 densities/amplitudes (nanovolts/degree2) were automatically determined within each concentric ring. Ring 1/2 and 1/3 ratios were calculated as the ratio of the central ring amplitude (ring 1) to the amplitudes generated from rings 2 and 3, respectively. Age-normal data specific to our institution had been obtained by the study of volunteers with normal visual function and without retinal pathology.
Table 1—Differences in ring amplitudes and ratios between the group that experienced recovery (n = 9) and the group with partial recovery (n = 4) of abnormal mfERG response after cessation of hydroxychloroquine therapy Variable
Age Normal Data, Range (nV)
At toxicity Ring 1 amplitude 12.9 32.3 Ring 2 amplitude 7.6 16.8 Ring 3 amplitude 4.8 10.0 Ring 1/2 ratio 1.16 2.95 Ring 1/3 ratio 2.5 3.2 First point of discontinuation Ring 1 amplitude Ring 2 amplitude Ring 3 amplitude Ring 1/2 ratio Ring 1/3 ratio At second point of discontinuation Ring 1 amplitude Ring 2 amplitude Ring 3 amplitude Ring 1/2 ratio Ring 1/3 ratio
Recovery, Mean § SD
Partial Recovery, Mean § SD
p
Effect Sizea
10.9 § 4.3 5.9 § 2.4 3.7 § 1.2 2.3 § 0.9 3.4 § 0.9
3.7 § 3.2 2.1 § 1.5 1.9 § 1.0 1.8 § 1.3 2.4 § 1.8
0.004 0.013 0.024 0.427 0.194
0.6 0.5 0.4
20.1 § 6.2 11.4 § 3.1 6.9 § 2.1 1.8 § 0.1 2.9 § 0.3
7.8 § 3.1 3.6 § 2.1 2.7 § 1.3 2.6 § 0.8 3.5 § 2.2
0.004 0.001 0.003 0.141 0.397
0.9 0.7 0.6
19.6 § 3.4 11.9 § 0.9 7.4 § 0.6 1.6 § 0.2 1.6 § 0.2
6.6 § 2.8 4.0 § 1.7 3.1 § 1.3 1.7 § 0.4 2.4 § 1.0
0.003 0.001 0.004 0.888 0.673
0.7 0.8 0.7
Effect size: quantitative measure of the effect of the change after therapy cessation (0.1 0.3 is small effect size, 0.3 0.7 is medium effect, and >0.7 is large effect or change).
a
2
CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al. Data analysis
The Statistical Package for Social Scientist 24 (SPSS; Chicago, Ill) was used to analyse the data. Descriptive statistics were used to analyse the patients’ clinical characteristics. Only data from the right eye (OD) were analysed as computed correlation coefficient values were high (>0.80), thus indicating lack of independence between the right (OD) and left (OS) eyes. Independent sample t test analysis was performed to determine differences in clinical characteristics between groups. One-way analysis of variance with repeated measures and post-hoc analysis was used to describe mfERG changes over a period of 4 years after the cessation of therapy.
TAGEDH1RESULTSTAGEDEN In total, 50 cases stopped hydroxychloroquine treatment and were identified as having retinopathy based on the agreement of 2 independent observers. Of these cases, sufficient data were available for 14 patients on their outcomes after the cessation of therapy. All 14 patients were female (2 Asian, 1 African, and 11 Caucasian). Twelve patients were treated for rheumatoid arthritis, whereas 2 patients were treated for systemic lupus erythematosus. The characteristics of the 14 patients are provided in Table 2. In 9 patients, mfERG ring amplitudes improved to the range of age normal responses (Tables 1,3,4, and Supplementary Table 1 [available online]) 3 4 years after therapy cessation. Greater ring amplitude reduction occurred among patients with limited recovery of mfERG response than in patients experiencing recovery of mfERG response (Table 5). Ring amplitudes reduced by >70% and <60%, respectively. Recovery of mfERG ring 1 amplitude occurred at the second point of examination after therapy cessation (Wilks’ λ = 0.01, F[2, 7.09], p = 0.001) using one-way analysis of variance with repeated measure and post-hoc analysis. The trend toward recovery of mfERG ring 2 amplitude occurred after the first point of examination after therapy cessation (Wilks’ λ = 0.65, F[2, 0.44], p = 0.003, effect size = 0.95). The trend toward improvement of mfERG ring 3 amplitude (Table 4) was
Table 3—Difference in patient characteristics after stopping hydroxychloroquine therapy (N = 13) Variable Age (y) Daily drug dose (mg/kg) Total daily drug dose (g) Cumulative dose (kg) Duration of therapy (y) Visual acuity (logMAR)
Recovery (n = 9), Mean § SD
Partial Recovery (n = 4), Mean § SD
p
56.6 § 9.4 5.5 § 2.0 366.7 § 122.5 1.4 § 0.6 10.3 § 4.3 0.8 § 0.2
65.5 § 3.4 6.4 § 7 375.5 § 50.0 1.9 § 0.4 14.3 § 4.6 0.8 § 0.1
0.096 0.508 0.900 0.192 0.159 0.446
Independent sample t-test analysis (significance: p > 0.05). Clinical characteristics were similar for both groups (p > 0.05).
observed on both the first and second points of examination after therapy cessation (Wilks’ λ = 0.02, F[2, 1.13], p = 0.014, effect size = 0.98). The earliest time from therapy cessation to improvement of the mfERG response was 3 months. Among patients who experienced improvement in mfERG ring amplitudes after therapy cessation, visual acuity was maintained, fundus images showed a normal appearance, and the SD-OCT (where data were available) images were normal (Supplementary Fig. 2, P1 P9 [available online]). However, some patients (P1, P3) presented with scotoma points or reduced visual field sensitivity. Four patients experienced limited improvement in mfERG ring amplitudes (still below the lower limit of the 95% confidence interval of age normal data) and one patient had no change in the abnormal mfERG response (with no further depression or improvement of mfERG ring amplitudes, within 10% intervisit variability). Table 5 shows the proportion reduction in ring amplitude from age normal values for the 2 groups. Case 1 is an example of a 63-year-old female who experienced recovery of a normal mfERG response after cessation of hydroxychloroquine therapy for rheumatoid arthritis. The patient was suspected to have hydroxychloroquine toxicity due to consistent decline in mfERG ring amplitudes and after 2 abnormal mf ERG test results (Fig. 1). At the point of suspected toxicity, the patient was on a daily hydroxychloroquine dose/real body weight of 6.17 mg/kg, and had received a cumulative dose of 2.19 kg, after a duration of 20 years.
Table 2—Characteristics of patients: the point of toxicity (N = 14) Case
Condition
Race
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14
SLE RA RA RA RA SLE RA RA RA RA RA RA RA RA
Caucasian Caucasian Caucasian African Caucasian Asian Asian Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian
Age (y)
Daily Dose/RBW (mg/kg)
Cumulative Dose (kg)
Duration of Therapy (y)
48 56 67 50 44 48 68 61 63 70 62 64 66 79
3.15 4.41 6.00 9.12 6.08 6.08 2.99 6.17 6.35 5.52 6.53 8.22 6.78 5.90
1.24 1.09 1.75 1.24 1.75 1.24 0.75 2.19 0.84 2.19 2.19 1.90 1.24 1.75
17 10 12 10 12 15 6 20 5.75 20 15 13 10 12
Visual Acuity (logMAR) OD
OS
0.00 0.00 0.10 0.00 0.00 0.10 0.10 0.10 0.30 0.10 0.10 0.10 0.10 0.18
0.00 0.18 0.00 0.00 0.10 0.00 0.00 0.00 0.18 0.10 0.10 0.30 0.00 0.18
RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; RBW, real body weight (kg). Patients were being treated with hydroxychloroquine at high daily drug dose (>5 mg/kg) except for P1, P2, and P7. Except for P7, all patients had been on long-term (>5 years) treatment.
CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
3
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al. Table 4—Changes in mfERG ring amplitudes after therapy discontinuation mfERG Parameter
pb
Mean Difference (SE)
95% Confidence Interval Lower Limit
Ring 1 T Ring 2 T Ring 3 T
Upper Limit
DC1 DC2
8.5 (1.4) 7.4* (0.8)
0.075 0.033
18.9 17.5
1.9 15.3
DC1 DC2
6.3a (0.7) 6.3 (1.1)
0.031 0.087
11.3 14.7
1.4 2.1
DC1 DC2
3.6* (0.4) 4.2* (0.5)
0.030 0.034
6.3 7.6
0.8 0.8
DC1, first test after cessation of therapy; T, test at toxicity; DC2, second test after cessation of therapy. One-way analysis of variance with repeated measure and post-hoc analysis. a Mean difference is significant at the 0.05 level. b Adjustment for multiple comparison—Bonferroni. *Statistically significant difference
Table 5—Proportion reduction in ring amplitude from age normal data for patients experiencing recovery of mfERG response (n = 9) and those experiencing partial recovery (n = 9) of mfERG response after therapy cessation mfERG Ring Amplitude (nV/degree2)
Group Mean
Normative Data Mean
Proportion of Reduction (%)
p
Effect Sizea
10.9 5.0 3.7
21.2 11.7 7.0
48.7 57.4 47.3
<0.001 <0.001 <0.001
1.2 1.2 1.1
4.1 1.9 2.0
20.1 11.3 6.8
78.5 82.6 70.1
<0.001 <0.001 <0.001
5.8 5.9 5.8
Recovery (n = 9) Ring 1 Ring 2 Ring 3 Partial recovery (n = 4) Ring 1 Ring 2 Ring 3
Significance, p < 0.05. Significant reduction in mfERG ring amplitudes occurred on rings 2 for both categories of patients (Ring 2 amplitude reduced by 57.4% for patients experiencing recovery of mfERG response and 82.6% reduction for patients with limited recovery of mfERG response). Patients with limited recovery of mfERG response had Ring 1, Ring 2, and Ring 3 amplitudes reduced by >70% at the point of toxicity compared to the less reduction of ring amplitudes of patients with recovery of mfERG response <60%. a Effect size = quantitative measure of the effect of the change after therapy cessation (0.1 0.3 is small effect size, 0.3 0.7 is medium effect, and >0.7 is large effect or change).
Ring amplitudes in nanoVolt/degree2
mfERG ring amplitude and ratio changes across time for a patient with abnormal test result in whom the abnormal response recovered 20 15 10 5 0 B1
B2
B3
T
T
DC1
DC2
Jun, 2011
Sept, 2012
Feb, 2013
Mar, 2014
Apr, 2015
Mar, 2016
Dec, 2016
Ring 1
Ring 2
Ring 3
Fig. 1—Case 1 (P8): Recovery of mfERG response after therapy cessation. B1, first baseline mfERG before toxicity; B2, second test before toxicity; B3, third test before toxicity; T, test at toxicity; DC1, first test after cessation of therapy; DC2, second test after cessation of therapy.
The two tests taken post-therapy show that the mfERG response improved after therapy discontinuation. The best corrected visual acuity (BCVA) was unchanged (20/20) from B1 to B3. BCVA at test toxicity was 20/25 (OD), 20/20 (OS), and 20/20 after the cessation of therapy. Case 2 is an example of advanced disease in a 67-year-old female who experienced partial recovery of normal mfERG response after cessation of hydroxychloroquine therapy Fig. 2. At the point of diagnosis, the mfERG implicit time was delayed (Supplementary Table 1, P12 [available online]). Case 2 also had significant disruption of the photoreceptor inner segment/outer segment junction (ellipsoid zone) seen
4
CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
with SD-OCT, a bull’s eye maculopathy, a partial and(or) full ring scotoma as seen with 10-2 HVF as seen in Fig. 3 examination, and retinal pigment epithelium loss with fundus autofluorescence imaging (Fig. 2, Supplementary Figs. 1 and 2, P12 and Supplementary Table 1 [available online]).The patient had accumulated a total hydroxychloroquine dose of 1.90 kg after 13 years of therapy (daily hydroxychloroquine dose = 8.22 mg/kg; Table 2, P12). BCVA (logMAR) worsened over time from 0.1 0.48, from the time toxicity was found to 4 years after the cessation of therapy (Supplementary Table 2 [available online]). As seen in Fig. 3, the mfERG response improved but not to age-adjusted normal values. Only a mild improvement in mfERG ring amplitude responses occurred after therapy cessation. BCVA progressively worsened even after discontinuation of therapy due to advanced hydroxychloroquine retinal toxicity: a BCVA (logMAR) of 0.3 0.48 (right eye only) (Supplementary Table 2, P12 [available online]).
TAGEDH1DISCUSSIONTAGEDEN The patients in this study were treated with a high daily hydroxychloroquine dose (n = 11, >5 mg/kg/day), with a corresponding high cumulative dose over the duration of therapy (n = 11, 10 years; Tables 2, 3), which are important risk factors for hydroxychloroquine retinopathy.5,6,20 From following these 14 patients, we observe that the course of the abnormal mfERG response among patients with suspected hydroxychloroquine retinopathy was dependent on the
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al.
Fig. 2—Case example 2. 3A, SD-OCT images reveal loss of central retinal pigment epithelium and photoreceptor outer segments; 3B, Fundus image with bull’s eye maculopathy.
Ring amplitudes in nanoVolt/degree2
mfERG ring amplitude changes across time for a patient with partial recovery of the mfERG response after therapy cessation 5 4.5 4 3.5 3 2.5 2 1.5 1 0.5 0 T
DC1
DC2
Jun 20, 2012
Dec 7, 2012
May 22, 2015
Ring 1
Ring 2
Ring 3
Fig. 3—Case 2 (P12): Limited recovery of abnormal mfERG response. T, mfERG test at toxicity; DC1, first test after cessation of hydroxychloroquine therapy; DC2, second test after cessation of therapy.
stage and(or) severity of disease when intervention (drug use was stopped) was instituted. Also, changes in mfERG responses appeared early in patients on hydroxychloroquine before structural changes were seen on SD-OCT. Even a point scotoma on 10-2 HVF in a patient (Supplementary Fig. 2, P1, and P3 [available online]) with a previously normal field may warrant suspicion of early hydroxychloroquine retinopathy. For example, P8, case example 1 (Fig. 1), experienced a gradual reduction in the mfERG over time. After therapy cessation, however, the mfERG response improved to within normal range. The SD-OCT image was observed to be normal at the point of toxicity (Supplementary Fig. 2, P8 [available online]) and visual acuity was preserved (Supplementary Table 2, P8 [available online]). The observation that early abnormal
mfERG response can be reversed in the early stages of hydroxychloroquine retinopathy had been previously proposed by Marmor and Hu10 in 2014 when they discussed the effect of disease stage on progression of hydroxychloroquine retinopathy among 11 patients who stopped drug use due to toxicity. Maturi et al.21 and Marmor and Hu10 also found that early cases of hydroxychloroquine retinopathy showed little or no change on SD-OCT while appearing to have point scotomas on 10-2 HVF and an abnormal mfERG response. Our 9 patients in whom the mfERG response improved also maintained good central vision (Supplementary Table 2, P1 P9, case example 1 [available online]) and normal SD-OCT findings (Supplementary Fig. 2, P1 P9 [available online]). CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
5
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al. Case example 2 represents advanced disease that is described in the literature as a point when patients experience progression even after therapy cessation.7,8,10 Hydroxychloroquine drug dose of >5 mg/kg/day and long-term therapy are 2 important risk factors for the development of hydroxychloroquine retinopathy.6 Mititelu et al.,8 Mavrikakis et al.,7 and Marmor and Hu10 have all reported that progression of hydroxychloroquine retinopathy is most likely once SDOCT photoreceptor ellipsoid zone loss occurs. Mititelu et al.8 concluded that an intact external limiting membrane and photoreceptor ellipsoid zone have prognostic value in determining regeneration or otherwise of the photoreceptor layer after hydroxychloroquine therapy cessation. Patients who experienced recovery and limited improvement of the amplitudes of the mfERG response had consumed high hydroxychloroquine daily drug dose over a long duration (Tables 2, 3). Although patients who experienced an improvement to within normative values or limited improvement did not differ in their clinical characteristics (p > 0.05), they differed in the proportional reduction in mfERG response from the age normal responses at the point of intervention (Tables 1, 5). The trend toward reversal occurred at the first point of examination after therapy cessation (Table 4). The 9 patients in whom the mfERG response improved to within normative values had a mfERG response reduced by <60% on ring 2 (Table 5) at the time of discontinuation of therapy. However, if the mfERG response was reduced by >70% from age normal response (Table 5), patients experienced a limited improvement of the mfERG response. The study is limited by its retrospective design, small sample size, and short follow-up time. As a result of its retrospective nature, some SD-OCT and 10-2 HVF data were lacking, thus limiting the assessment of structural and visual field changes after therapy cessation. Further studies with a larger sample of patients in whom hydroxychloroquine was discontinued, followed over a longer time line, may give insight as to whether a normal response will be eventually restored in patients with limited improvement or whether patients in whom a normal mfERG response was recovered will eventually show toxicity or remain stable. Future studies could compare sensitivity and specificity of mfERG, SDOCT, and 10-2 HVF in the early detection of hydroxychloroquine retinal toxicity and monitoring the course of disease after therapy discontinuation.
TAGEDH1CONCLUSIONSTAGEDEN This study provides evidence that discontinuing hydroxychloroquine therapy at a critical point may allow improvement in mfERG function. Patients who show a consecutive and consistent decline in ring amplitudes could recover an mfERG response within normative values if hydroxychloroquine therapy is discontinued before the ring amplitudes are reduced below 50% of age-adjusted normative limits. Once the mfERG ring amplitudes were reduced by >70%, improvement in mfERG response was limited despite therapy cessation.
6
CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
TAGEDH1SUPPLEMENTARY MATERIALSTAGEDEN Supplementary material associated with this article can be found in the online version at doi:10.1016/j.jcjo.2019.05.013. TAGEDH1REFERENCESTAGEDEN 1. Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. 2013;43:264–72. 2. Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2013;6:35–43. 3. Gaujoux-Viala C, Smolen SJ, Landewe R, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1004–9. 4. Izmirly PM, Nathalie Costedoat-Chalumeau N, Pisoni C, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-ssa/ro associated cardiac manifestations of neonatal lupus. Circulation. 2012;126:76–82. 5. Marmor MF, Kellner U, Lai TYY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386–94. 6. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132: 1453–60. 7. Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology. 2003;110:1321–6. 8. Mititelu M, Wong BJ, Brenner M, et al. Progression of hydroxychloroquine toxic effects after drug therapy cessation. JAMA Ophthalmol. 2013;131:1187–97. 9. de Sisternes L, Hu J, Rubin DL, et al. Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Invest Ophthalmol Vis Sci. 2015;56:3415–26. 10. Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol. 2014;132:1105–12. 11. Marmor M, Kellner U, Lai T, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;11:415–22. 12. Spaide RF, Curcio CA. Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina. 2011;31:1609–19. 13. Cukras C, Huynh N, Vitale S, et al. Subjective and objective screening tests for hydroxychloroquine toxicity. Ophthalmology. 2015;122: 356–66. 14. Chen E, Brown DM, Benz MS, et al. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the flying saucer sign). Clin Ophthalmol. 2010;4:1151–8. 15. Lyons JS, Severns ML. Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review. Doc Ophthalmol. 2009;118: 29–36. 16. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol. 2007;143:801–9. 17. Browning DJ, Lee C. Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. Clin Ophthalmol. 2014;8:1389–99. 18. Hood DC, Bach M, Brigell M, et al. ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol. 2012;124:1–13. 19. Hood DC, Bach M, Brigell M, et al. ISCEV guidelines for clinical multifocal electroretinography (2007 edition). Doc Ophthalmol. 2008;116:1–11. 20. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775–84. 21. Maturi RK, Yu M, Weleber R. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol. 2004;122:973–81.
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al.
Footnotes and Disclosure: Supported by: Beatrice Adamptey gratefully acknowledges the financial support from Edwin Isaac Clarke Scholarship for Ophthalmology Research at the University of Alberta. From the Department of Ophthalmology and Visual Sciences, University of Alberta, Edmonton, Alta.
Originally received Feb. 11, 2019. Final revision May. 19, 2019. Accepted May. 20, 2019. Correspondence to Ian MacDonald, MSc, Ophthalmology and Visual Sciences, University of Alberta, 2305 ATC Royal Alex Hospital, 10240 Kingsway Ave., Edmonton, Alta. T5H3V9. [email protected]
CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
7
Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram in patients with rheumatic disorders Beatrice Adamptey, OD, MSc, Christopher J. Rudnisky, MD, MPH, Ian M. MacDonald, MSc, MDCM ABSTRACT Objective: To report the effect of hydroxychloroquine therapy cessation on the multifocal electroretinogram (mfERG) in a case series of patients with rheumatic disease suspected to have retinopathy. Methods: Comprehensive data were retrospectively reviewed on 14 patients from a total of 50 cases who discontinued hydroxychloroquine due to suspected toxicity. Patients were followed for 4 years after the cessation of therapy. mfERG testing had been part of original screening for hydroxychloroquine retinopathy and was continued after therapy cessation at 6-month intervals. Descriptive statistics, independent sample t test, and one-way analysis of variance with repeated measures and post hoc analysis were conducted to determine patients’ clinical characteristics and changes in the mfERG after therapy cessation, respectively. Results: All 14 patients were female; 12 were treated for rheumatoid arthritis and 2 for systemic lupus erythematosus. Three groups were identified: (i) 9 patients in whom the responses of the mfERG recovered to within normative values after cessation of hydroxychloroquine therapy, (ii) 3 who experienced limited recoveries, and (iii) 1 patient whose mfERG response was unchanged. There was no significant difference (p > 0.05) in the clinical characteristics of these patients. However, the proportional reduction of mfERG ring 1, 2, and 3 amplitudes from age normal responses at the time of discontinuation of drug use for the first and second groups of patients was significantly different, with more reduction in group 2 (p < 0.05). Conclusion: Early detection of hydroxychloroquine retinopathy through screening and subsequent therapy discontinuation could result in recovery of the mfERG ring amplitude response and preservation of visual function.
Hydroxychloroquine is widely used in North America to manage inflammatory and autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.1,2 Hydroxychloroquine is preferred over chloroquine because of its relatively safer profile, with less adverse effect on retinal structure and function.3,4 Hydroxychloroquine retinopathy is a concern for patients, especially those taking the drug for more than 5 years.5,6 With the application of more sensitive screening tests capable of detecting retinopathy at the premaculopathy stage, such as multifocal electroretinography (mfERG) and spectral domain optical coherence tomography (SD-OCT), the prevalence of hydroxychloroquine retinopathy could be higher than previously reported.5,6 There is currently no available treatment for hydroxychloroquine retinopathy.7 Once diagnosed, cessation is recommended to limit or halt progression of retinal toxicity. Only a few small studies have reported the course of hydroxychloroquine retinopathy after cessation of therapy using more sensitive tests such as the mfERG.7 9 Marmor and Hu10 and Mititelu et al.8 reported that the course of hydroxychloroquine retinopathy (recovery, progression, or stability) was determined by the stage of disease at which patients discontinued therapy. They indicated that disease progressed even with cessation, thus advocating for early detection. In 2016, the American Academy of Ophthalmology recommended the use of more sensitive and specific tests, such
as the mfERG, for the early detection of hydroxychloroquine retinopathy.5,11 Our study therefore reports the outcome of a cohort of patients on hydroxychloroquine for rheumatic disorders based on the American Academy of Ophthalmology guidelines and the response of a select number for whom cessation of therapy had been recommended. The study also determined what factors influenced the recovery or progression of abnormal mfERG responses to guide physicians’ decisions on drug discontinuation to prevent vision loss.
TAGEDH1METHODOLOGYTAGEDEN We retrospectively reviewed the medical records of 623 patients screened for hydroxychloroquine retinopathy with the use of mfERG at the Royal Alexandra Hospital, Edmonton, from January 2008 and December 2016. The medical records of these patients were captured in a secure diagnostic electronic database at the Eye Institute of Alberta . In general, patients in this dataset had mfERG testing as a baseline test, or to document functional loss from concurrent maculopathy or to rule out hydroxychloroquine retinopathy. The study received a waiver of consent from the Health Research Ethics Board of the University of Alberta and operational approval from Alberta Health Services, Edmonton.
© 2019 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved. https://doi.org/10.1016/j.jcjo.2019.05.013 ISSN 0008-4182 CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
1
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al. Inclusion criteria
Cases of hydroxychloroquine retinopathy were included based on the opinions of 2 independent observers reviewing fundus examination, fundus photography, fundus autofluorescence, mfERG, SD-OCT, and 10-2 Humphrey visual field (HVF). Hydroxychloroquine retinopathy was defined as at least 2 abnormal functional tests (mfERG, SD-OCT, or 10-2 HVF), patient symptoms, and an abnormal fundus examination. Testing abnormalities were defined as a full or partial ring scotoma on a 10-2 HVF examination,6 or disruption of the photoreceptor ellipsoid zone on SD-OCT.6,12 14 For the mfERG, hydroxychloroquine retinopathy was defined as ring 1, 2, and 3 amplitudes reduced below the lower limit of the 95% confidence interval of age normal data (Table 1), with or without elevated ring 1/2 and/ 1/3 ratios, and with or without delayed implicit time.13,15,16 Exclusion criteria
Cases without agreement of independent examiners on presumed hydroxychloroquine retinopathy and those for whom insufficient information was available during a period of follow-up were excluded. For some patients, follow-up mfERG testing was not ordered by the referring clinician. Subgroup analysis
Cases in which hydroxychloroquine retinopathy was identified and therapy stopped were followed up to 4 years after the cessation of therapy. These cases had clear, legible 10-2 HVF, SD-OCT, and mfERG test images; multiple testing with mfERG (no 60 cycle noise)17; no artifacts on SD-OCT imaging; and reliable 10-2 HVF (<20% false-negative and false-positive rates and <10% fixation losses). Visual field test acquisition
Visual fields were generated by the HVF 10-2 program visual field analyser, white stimulus test target, and SITA-standard protocol (Carl Zeiss Meditec, Dublin, Calif).
Spectral domain optical coherence tomography image acquisition
Foveal centred volume scans with Spectralis tracking laser tomography (Spectralis Heidelberg Engineering, Carlsbad, Calif) system were acquired by 4 ophthalmic technicians. 10-2 HVF field and SD-OCT images are reported where available in Supplementary Figure 2, which is available online. Two patients with coincident retinal disease and/or 8 patients with incomplete data were excluded from the analysis. For each patient, data were collected on therapy duration (start and end date of therapy, daily drug dose (mg/kg), cumulative drug dose (kg), height (m), weight (kg), sex, age, and racial background. Multifocal electroretinogram response acquisition
mfERG imaging was recorded in accordance with the standards of the International Society for Clinical Electrophysiology of Vision18,19 with DTL fibre electrodes using the 2015 model of the Espion system 6+ (Diagnosys LLC, Lowell, Mass) software. The pupils of patients were dilated with 1% tropicamide to a size of >8 mm before the acquisition of mfERG responses. The m-sequence-controlled, 61-hexagon black and white stimulus pattern was used traversing a visual field of 30° on either side of the point of fixation. The black and white hexagons had a luminance of 1000 and 0 cd/m2, respectively. The waveforms (negative trough N1 and positive peak P1) generated from continuous stimulation of the retina by each of the 61 hexagons were processed through the 10 100 Hz bandpass filter. The Espion system version 6+ software analysed the response of the first-order kernel. The average rings 1 3 densities/amplitudes (nanovolts/degree2) were automatically determined within each concentric ring. Ring 1/2 and 1/3 ratios were calculated as the ratio of the central ring amplitude (ring 1) to the amplitudes generated from rings 2 and 3, respectively. Age-normal data specific to our institution had been obtained by the study of volunteers with normal visual function and without retinal pathology.
Table 1—Differences in ring amplitudes and ratios between the group that experienced recovery (n = 9) and the group with partial recovery (n = 4) of abnormal mfERG response after cessation of hydroxychloroquine therapy Variable
Age Normal Data, Range (nV)
At toxicity Ring 1 amplitude 12.9 32.3 Ring 2 amplitude 7.6 16.8 Ring 3 amplitude 4.8 10.0 Ring 1/2 ratio 1.16 2.95 Ring 1/3 ratio 2.5 3.2 First point of discontinuation Ring 1 amplitude Ring 2 amplitude Ring 3 amplitude Ring 1/2 ratio Ring 1/3 ratio At second point of discontinuation Ring 1 amplitude Ring 2 amplitude Ring 3 amplitude Ring 1/2 ratio Ring 1/3 ratio
Recovery, Mean § SD
Partial Recovery, Mean § SD
p
Effect Sizea
10.9 § 4.3 5.9 § 2.4 3.7 § 1.2 2.3 § 0.9 3.4 § 0.9
3.7 § 3.2 2.1 § 1.5 1.9 § 1.0 1.8 § 1.3 2.4 § 1.8
0.004 0.013 0.024 0.427 0.194
0.6 0.5 0.4
20.1 § 6.2 11.4 § 3.1 6.9 § 2.1 1.8 § 0.1 2.9 § 0.3
7.8 § 3.1 3.6 § 2.1 2.7 § 1.3 2.6 § 0.8 3.5 § 2.2
0.004 0.001 0.003 0.141 0.397
0.9 0.7 0.6
19.6 § 3.4 11.9 § 0.9 7.4 § 0.6 1.6 § 0.2 1.6 § 0.2
6.6 § 2.8 4.0 § 1.7 3.1 § 1.3 1.7 § 0.4 2.4 § 1.0
0.003 0.001 0.004 0.888 0.673
0.7 0.8 0.7
Effect size: quantitative measure of the effect of the change after therapy cessation (0.1 0.3 is small effect size, 0.3 0.7 is medium effect, and >0.7 is large effect or change).
a
2
CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al. Data analysis
The Statistical Package for Social Scientist 24 (SPSS; Chicago, Ill) was used to analyse the data. Descriptive statistics were used to analyse the patients’ clinical characteristics. Only data from the right eye (OD) were analysed as computed correlation coefficient values were high (>0.80), thus indicating lack of independence between the right (OD) and left (OS) eyes. Independent sample t test analysis was performed to determine differences in clinical characteristics between groups. One-way analysis of variance with repeated measures and post-hoc analysis was used to describe mfERG changes over a period of 4 years after the cessation of therapy.
TAGEDH1RESULTSTAGEDEN In total, 50 cases stopped hydroxychloroquine treatment and were identified as having retinopathy based on the agreement of 2 independent observers. Of these cases, sufficient data were available for 14 patients on their outcomes after the cessation of therapy. All 14 patients were female (2 Asian, 1 African, and 11 Caucasian). Twelve patients were treated for rheumatoid arthritis, whereas 2 patients were treated for systemic lupus erythematosus. The characteristics of the 14 patients are provided in Table 2. In 9 patients, mfERG ring amplitudes improved to the range of age normal responses (Tables 1,3,4, and Supplementary Table 1 [available online]) 3 4 years after therapy cessation. Greater ring amplitude reduction occurred among patients with limited recovery of mfERG response than in patients experiencing recovery of mfERG response (Table 5). Ring amplitudes reduced by >70% and <60%, respectively. Recovery of mfERG ring 1 amplitude occurred at the second point of examination after therapy cessation (Wilks’ λ = 0.01, F[2, 7.09], p = 0.001) using one-way analysis of variance with repeated measure and post-hoc analysis. The trend toward recovery of mfERG ring 2 amplitude occurred after the first point of examination after therapy cessation (Wilks’ λ = 0.65, F[2, 0.44], p = 0.003, effect size = 0.95). The trend toward improvement of mfERG ring 3 amplitude (Table 4) was
Table 3—Difference in patient characteristics after stopping hydroxychloroquine therapy (N = 13) Variable Age (y) Daily drug dose (mg/kg) Total daily drug dose (g) Cumulative dose (kg) Duration of therapy (y) Visual acuity (logMAR)
Recovery (n = 9), Mean § SD
Partial Recovery (n = 4), Mean § SD
p
56.6 § 9.4 5.5 § 2.0 366.7 § 122.5 1.4 § 0.6 10.3 § 4.3 0.8 § 0.2
65.5 § 3.4 6.4 § 7 375.5 § 50.0 1.9 § 0.4 14.3 § 4.6 0.8 § 0.1
0.096 0.508 0.900 0.192 0.159 0.446
Independent sample t-test analysis (significance: p > 0.05). Clinical characteristics were similar for both groups (p > 0.05).
observed on both the first and second points of examination after therapy cessation (Wilks’ λ = 0.02, F[2, 1.13], p = 0.014, effect size = 0.98). The earliest time from therapy cessation to improvement of the mfERG response was 3 months. Among patients who experienced improvement in mfERG ring amplitudes after therapy cessation, visual acuity was maintained, fundus images showed a normal appearance, and the SD-OCT (where data were available) images were normal (Supplementary Fig. 2, P1 P9 [available online]). However, some patients (P1, P3) presented with scotoma points or reduced visual field sensitivity. Four patients experienced limited improvement in mfERG ring amplitudes (still below the lower limit of the 95% confidence interval of age normal data) and one patient had no change in the abnormal mfERG response (with no further depression or improvement of mfERG ring amplitudes, within 10% intervisit variability). Table 5 shows the proportion reduction in ring amplitude from age normal values for the 2 groups. Case 1 is an example of a 63-year-old female who experienced recovery of a normal mfERG response after cessation of hydroxychloroquine therapy for rheumatoid arthritis. The patient was suspected to have hydroxychloroquine toxicity due to consistent decline in mfERG ring amplitudes and after 2 abnormal mf ERG test results (Fig. 1). At the point of suspected toxicity, the patient was on a daily hydroxychloroquine dose/real body weight of 6.17 mg/kg, and had received a cumulative dose of 2.19 kg, after a duration of 20 years.
Table 2—Characteristics of patients: the point of toxicity (N = 14) Case
Condition
Race
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14
SLE RA RA RA RA SLE RA RA RA RA RA RA RA RA
Caucasian Caucasian Caucasian African Caucasian Asian Asian Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian
Age (y)
Daily Dose/RBW (mg/kg)
Cumulative Dose (kg)
Duration of Therapy (y)
48 56 67 50 44 48 68 61 63 70 62 64 66 79
3.15 4.41 6.00 9.12 6.08 6.08 2.99 6.17 6.35 5.52 6.53 8.22 6.78 5.90
1.24 1.09 1.75 1.24 1.75 1.24 0.75 2.19 0.84 2.19 2.19 1.90 1.24 1.75
17 10 12 10 12 15 6 20 5.75 20 15 13 10 12
Visual Acuity (logMAR) OD
OS
0.00 0.00 0.10 0.00 0.00 0.10 0.10 0.10 0.30 0.10 0.10 0.10 0.10 0.18
0.00 0.18 0.00 0.00 0.10 0.00 0.00 0.00 0.18 0.10 0.10 0.30 0.00 0.18
RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; RBW, real body weight (kg). Patients were being treated with hydroxychloroquine at high daily drug dose (>5 mg/kg) except for P1, P2, and P7. Except for P7, all patients had been on long-term (>5 years) treatment.
CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
3
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al. Table 4—Changes in mfERG ring amplitudes after therapy discontinuation mfERG Parameter
pb
Mean Difference (SE)
95% Confidence Interval Lower Limit
Ring 1 T Ring 2 T Ring 3 T
Upper Limit
DC1 DC2
8.5 (1.4) 7.4* (0.8)
0.075 0.033
18.9 17.5
1.9 15.3
DC1 DC2
6.3a (0.7) 6.3 (1.1)
0.031 0.087
11.3 14.7
1.4 2.1
DC1 DC2
3.6* (0.4) 4.2* (0.5)
0.030 0.034
6.3 7.6
0.8 0.8
DC1, first test after cessation of therapy; T, test at toxicity; DC2, second test after cessation of therapy. One-way analysis of variance with repeated measure and post-hoc analysis. a Mean difference is significant at the 0.05 level. b Adjustment for multiple comparison—Bonferroni. *Statistically significant difference
Table 5—Proportion reduction in ring amplitude from age normal data for patients experiencing recovery of mfERG response (n = 9) and those experiencing partial recovery (n = 9) of mfERG response after therapy cessation mfERG Ring Amplitude (nV/degree2)
Group Mean
Normative Data Mean
Proportion of Reduction (%)
p
Effect Sizea
10.9 5.0 3.7
21.2 11.7 7.0
48.7 57.4 47.3
<0.001 <0.001 <0.001
1.2 1.2 1.1
4.1 1.9 2.0
20.1 11.3 6.8
78.5 82.6 70.1
<0.001 <0.001 <0.001
5.8 5.9 5.8
Recovery (n = 9) Ring 1 Ring 2 Ring 3 Partial recovery (n = 4) Ring 1 Ring 2 Ring 3
Significance, p < 0.05. Significant reduction in mfERG ring amplitudes occurred on rings 2 for both categories of patients (Ring 2 amplitude reduced by 57.4% for patients experiencing recovery of mfERG response and 82.6% reduction for patients with limited recovery of mfERG response). Patients with limited recovery of mfERG response had Ring 1, Ring 2, and Ring 3 amplitudes reduced by >70% at the point of toxicity compared to the less reduction of ring amplitudes of patients with recovery of mfERG response <60%. a Effect size = quantitative measure of the effect of the change after therapy cessation (0.1 0.3 is small effect size, 0.3 0.7 is medium effect, and >0.7 is large effect or change).
Ring amplitudes in nanoVolt/degree2
mfERG ring amplitude and ratio changes across time for a patient with abnormal test result in whom the abnormal response recovered 20 15 10 5 0 B1
B2
B3
T
T
DC1
DC2
Jun, 2011
Sept, 2012
Feb, 2013
Mar, 2014
Apr, 2015
Mar, 2016
Dec, 2016
Ring 1
Ring 2
Ring 3
Fig. 1—Case 1 (P8): Recovery of mfERG response after therapy cessation. B1, first baseline mfERG before toxicity; B2, second test before toxicity; B3, third test before toxicity; T, test at toxicity; DC1, first test after cessation of therapy; DC2, second test after cessation of therapy.
The two tests taken post-therapy show that the mfERG response improved after therapy discontinuation. The best corrected visual acuity (BCVA) was unchanged (20/20) from B1 to B3. BCVA at test toxicity was 20/25 (OD), 20/20 (OS), and 20/20 after the cessation of therapy. Case 2 is an example of advanced disease in a 67-year-old female who experienced partial recovery of normal mfERG response after cessation of hydroxychloroquine therapy Fig. 2. At the point of diagnosis, the mfERG implicit time was delayed (Supplementary Table 1, P12 [available online]). Case 2 also had significant disruption of the photoreceptor inner segment/outer segment junction (ellipsoid zone) seen
4
CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
with SD-OCT, a bull’s eye maculopathy, a partial and(or) full ring scotoma as seen with 10-2 HVF as seen in Fig. 3 examination, and retinal pigment epithelium loss with fundus autofluorescence imaging (Fig. 2, Supplementary Figs. 1 and 2, P12 and Supplementary Table 1 [available online]).The patient had accumulated a total hydroxychloroquine dose of 1.90 kg after 13 years of therapy (daily hydroxychloroquine dose = 8.22 mg/kg; Table 2, P12). BCVA (logMAR) worsened over time from 0.1 0.48, from the time toxicity was found to 4 years after the cessation of therapy (Supplementary Table 2 [available online]). As seen in Fig. 3, the mfERG response improved but not to age-adjusted normal values. Only a mild improvement in mfERG ring amplitude responses occurred after therapy cessation. BCVA progressively worsened even after discontinuation of therapy due to advanced hydroxychloroquine retinal toxicity: a BCVA (logMAR) of 0.3 0.48 (right eye only) (Supplementary Table 2, P12 [available online]).
TAGEDH1DISCUSSIONTAGEDEN The patients in this study were treated with a high daily hydroxychloroquine dose (n = 11, >5 mg/kg/day), with a corresponding high cumulative dose over the duration of therapy (n = 11, 10 years; Tables 2, 3), which are important risk factors for hydroxychloroquine retinopathy.5,6,20 From following these 14 patients, we observe that the course of the abnormal mfERG response among patients with suspected hydroxychloroquine retinopathy was dependent on the
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al.
Fig. 2—Case example 2. 3A, SD-OCT images reveal loss of central retinal pigment epithelium and photoreceptor outer segments; 3B, Fundus image with bull’s eye maculopathy.
Ring amplitudes in nanoVolt/degree2
mfERG ring amplitude changes across time for a patient with partial recovery of the mfERG response after therapy cessation 5 4.5 4 3.5 3 2.5 2 1.5 1 0.5 0 T
DC1
DC2
Jun 20, 2012
Dec 7, 2012
May 22, 2015
Ring 1
Ring 2
Ring 3
Fig. 3—Case 2 (P12): Limited recovery of abnormal mfERG response. T, mfERG test at toxicity; DC1, first test after cessation of hydroxychloroquine therapy; DC2, second test after cessation of therapy.
stage and(or) severity of disease when intervention (drug use was stopped) was instituted. Also, changes in mfERG responses appeared early in patients on hydroxychloroquine before structural changes were seen on SD-OCT. Even a point scotoma on 10-2 HVF in a patient (Supplementary Fig. 2, P1, and P3 [available online]) with a previously normal field may warrant suspicion of early hydroxychloroquine retinopathy. For example, P8, case example 1 (Fig. 1), experienced a gradual reduction in the mfERG over time. After therapy cessation, however, the mfERG response improved to within normal range. The SD-OCT image was observed to be normal at the point of toxicity (Supplementary Fig. 2, P8 [available online]) and visual acuity was preserved (Supplementary Table 2, P8 [available online]). The observation that early abnormal
mfERG response can be reversed in the early stages of hydroxychloroquine retinopathy had been previously proposed by Marmor and Hu10 in 2014 when they discussed the effect of disease stage on progression of hydroxychloroquine retinopathy among 11 patients who stopped drug use due to toxicity. Maturi et al.21 and Marmor and Hu10 also found that early cases of hydroxychloroquine retinopathy showed little or no change on SD-OCT while appearing to have point scotomas on 10-2 HVF and an abnormal mfERG response. Our 9 patients in whom the mfERG response improved also maintained good central vision (Supplementary Table 2, P1 P9, case example 1 [available online]) and normal SD-OCT findings (Supplementary Fig. 2, P1 P9 [available online]). CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
5
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al. Case example 2 represents advanced disease that is described in the literature as a point when patients experience progression even after therapy cessation.7,8,10 Hydroxychloroquine drug dose of >5 mg/kg/day and long-term therapy are 2 important risk factors for the development of hydroxychloroquine retinopathy.6 Mititelu et al.,8 Mavrikakis et al.,7 and Marmor and Hu10 have all reported that progression of hydroxychloroquine retinopathy is most likely once SDOCT photoreceptor ellipsoid zone loss occurs. Mititelu et al.8 concluded that an intact external limiting membrane and photoreceptor ellipsoid zone have prognostic value in determining regeneration or otherwise of the photoreceptor layer after hydroxychloroquine therapy cessation. Patients who experienced recovery and limited improvement of the amplitudes of the mfERG response had consumed high hydroxychloroquine daily drug dose over a long duration (Tables 2, 3). Although patients who experienced an improvement to within normative values or limited improvement did not differ in their clinical characteristics (p > 0.05), they differed in the proportional reduction in mfERG response from the age normal responses at the point of intervention (Tables 1, 5). The trend toward reversal occurred at the first point of examination after therapy cessation (Table 4). The 9 patients in whom the mfERG response improved to within normative values had a mfERG response reduced by <60% on ring 2 (Table 5) at the time of discontinuation of therapy. However, if the mfERG response was reduced by >70% from age normal response (Table 5), patients experienced a limited improvement of the mfERG response. The study is limited by its retrospective design, small sample size, and short follow-up time. As a result of its retrospective nature, some SD-OCT and 10-2 HVF data were lacking, thus limiting the assessment of structural and visual field changes after therapy cessation. Further studies with a larger sample of patients in whom hydroxychloroquine was discontinued, followed over a longer time line, may give insight as to whether a normal response will be eventually restored in patients with limited improvement or whether patients in whom a normal mfERG response was recovered will eventually show toxicity or remain stable. Future studies could compare sensitivity and specificity of mfERG, SDOCT, and 10-2 HVF in the early detection of hydroxychloroquine retinal toxicity and monitoring the course of disease after therapy discontinuation.
TAGEDH1CONCLUSIONSTAGEDEN This study provides evidence that discontinuing hydroxychloroquine therapy at a critical point may allow improvement in mfERG function. Patients who show a consecutive and consistent decline in ring amplitudes could recover an mfERG response within normative values if hydroxychloroquine therapy is discontinued before the ring amplitudes are reduced below 50% of age-adjusted normative limits. Once the mfERG ring amplitudes were reduced by >70%, improvement in mfERG response was limited despite therapy cessation.
6
CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
TAGEDH1SUPPLEMENTARY MATERIALSTAGEDEN Supplementary material associated with this article can be found in the online version at doi:10.1016/j.jcjo.2019.05.013. TAGEDH1REFERENCESTAGEDEN 1. Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. 2013;43:264–72. 2. Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2013;6:35–43. 3. Gaujoux-Viala C, Smolen SJ, Landewe R, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1004–9. 4. Izmirly PM, Nathalie Costedoat-Chalumeau N, Pisoni C, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-ssa/ro associated cardiac manifestations of neonatal lupus. Circulation. 2012;126:76–82. 5. Marmor MF, Kellner U, Lai TYY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386–94. 6. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132: 1453–60. 7. Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology. 2003;110:1321–6. 8. Mititelu M, Wong BJ, Brenner M, et al. Progression of hydroxychloroquine toxic effects after drug therapy cessation. JAMA Ophthalmol. 2013;131:1187–97. 9. de Sisternes L, Hu J, Rubin DL, et al. Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Invest Ophthalmol Vis Sci. 2015;56:3415–26. 10. Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol. 2014;132:1105–12. 11. Marmor M, Kellner U, Lai T, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;11:415–22. 12. Spaide RF, Curcio CA. Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina. 2011;31:1609–19. 13. Cukras C, Huynh N, Vitale S, et al. Subjective and objective screening tests for hydroxychloroquine toxicity. Ophthalmology. 2015;122: 356–66. 14. Chen E, Brown DM, Benz MS, et al. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the flying saucer sign). Clin Ophthalmol. 2010;4:1151–8. 15. Lyons JS, Severns ML. Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review. Doc Ophthalmol. 2009;118: 29–36. 16. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol. 2007;143:801–9. 17. Browning DJ, Lee C. Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. Clin Ophthalmol. 2014;8:1389–99. 18. Hood DC, Bach M, Brigell M, et al. ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol. 2012;124:1–13. 19. Hood DC, Bach M, Brigell M, et al. ISCEV guidelines for clinical multifocal electroretinography (2007 edition). Doc Ophthalmol. 2008;116:1–11. 20. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775–84. 21. Maturi RK, Yu M, Weleber R. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol. 2004;122:973–81.
ARTICLE IN PRESS Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram—Adamptey et al.
Footnotes and Disclosure: Supported by: Beatrice Adamptey gratefully acknowledges the financial support from Edwin Isaac Clarke Scholarship for Ophthalmology Research at the University of Alberta. From the Department of Ophthalmology and Visual Sciences, University of Alberta, Edmonton, Alta.
Originally received Feb. 11, 2019. Final revision May. 19, 2019. Accepted May. 20, 2019. Correspondence to Ian MacDonald, MSc, Ophthalmology and Visual Sciences, University of Alberta, 2305 ATC Royal Alex Hospital, 10240 Kingsway Ave., Edmonton, Alta. T5H3V9. [email protected]
CAN J OPHTHALMOL—VOL. &, NO. &, & 2019
7